The Industry

June 2008
Pharmaceutical Representative;Jun2008, Vol. 38 Issue 6, p10
The article presents global news briefs related to the pharmaceutical industry. TAP Pharmaceutical Products have signed an agreement to copromote Shire's Lialda (mesalamine), a once-daily ulcerative colitis drug. The European Commission has cleared the use of thalidomide pharmion in combination with melphalan and prednisone to treat multiple myeloma. Piramed, a privately held biotech company in Great Britain, was bought by Roche for $160 million.


Related Articles

  • Global Report.  // Pharmaceutical Representative;Nov2011, Vol. 41 Issue 11, p10 

    The article offers information related to the pharmaceutical industry such as the end of the deal to supply drugs between Roche and the state-funded hospitals in Greece, and the adoption by the European Commission (EC) of the revised proposals on supplying prescription-only drugs to the public.

  • Lymphoma Update.  // PharmaWatch: Cancer;Aug2006, Vol. 5 Issue 8, p7 

    The article provides update related to lymphoma. The European Commission has approved Roche Pharmaceuticals' MabThera as maintenance therapy for patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Data from an initial phase II clinical trial of Favrille Inc.'s investigational...

  • Pharmaceutical Spotlights.  // Conference & Incentive Travel;Jul/Aug2011 Brand Book, p75 

    The article offers information on the event management divisions of several companies in the British pharmaceutical industry including Meditronic Inc., F. Hoffmann-La Roche Ltd., and Shire Pharmaceuticals Ltd.

  • Alliances Update.  // PharmaWatch: Biotechnology;Oct2009, Vol. 8 Issue 10, p14 

    The article offers updates related to strategic alliances in the pharmaceutical industry. The PTC Therapeutics Inc. has signed an exclusive research collaboration and licensing agreement with Roche Holding AG to develop orally bioavailable small molecules. Nuevolution A/S has collaborated into a...

  • Neurology News Headlines March 15, 2004 - April 14, 2004.  // PharmaWatch: CNS;May 2004, Vol. 3 Issue 5, p6 

    Reports developments related to pharmaceutical industry as of April 2004. Acquisition of a patent licence portfolio by Evotec OIA AG from Roche Inc.; Procurement of marketing rights for Reminyl drug by Shire Pharmaceuticals Group PLC; Approval granted to Boston Life Sciences Inc. from the U.S....

  • PAIN & PYREXIA.  // Monthly Prescribing Reference;Dec2009, Vol. 25 Issue 12, p262 

    The article offers information on several drugs for the treatment of pain and pyrexia and discusses their indications, contraindications and precautions. Anaprox from Roche Pharmaceutical Co. is used in treating mild to moderate pain. Bayer from Bayer Consumer Care is used for the treatment of...

  • PAIN & PYREXIA.  // Monthly Prescribing Reference;Jun2011, Vol. 27 Issue 6, p269 

    The article offers information on the drugs for curing pain and pyrexia. Carbatrol from Shire Pharmaceuticals Group PLC can be used for treating trigeminal or glossopharyngeal neuralgia. Anaprox from F. Hoffmann-La Roche Ltd. can relieve mild to moderate pain, while Cataflam from Novartis AG can...

  • Roche.  // Formulary;Oct2000 Resource Guide, Vol. 35 Issue 10, p83 

    Features the Roche Holding Ltd., a pharmaceutical manufacturer. Focus of its international research and development efforts; Total shares at the biotechnology company, Genentech Inc.; Pharmaceutical products that have received approval from the United States Food and Drug Administration.

  • Legal costs batter Roche's profits. Beacham, Will // European Chemical News;3/3/2003, Vol. 78 Issue 2042, p9 

    Reports the financial performance of Swiss pharmaceutical company Roche in 2002. Factors that influenced its financial performance; Overview of its financial results; Expectations for 2003.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics